Shoreline Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Shoreline Biosciences's estimated annual revenue is currently $14.7M per year.
- Shoreline Biosciences's estimated revenue per employee is $188,782
- Shoreline Biosciences's total funding is $186M.
- Shoreline Biosciences has 78 Employees.
- Shoreline Biosciences grew their employee count by 42% last year.
Shoreline Biosciences Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Shoreline Biosciences?
Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.keywords:N/A
Number of Employees
Employee Growth %
Shoreline Biosciences News
Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells...
Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells.
SHORELINE BIOSCIENCES ANNOUNCES ORAL PRESENTATION on ipsc-derived NK cell (iNK) platform AT INNATE KILLER SUMMIT meeting 2022.
SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapie ...
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biotechnology co ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|